AXIN1

Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results

Retrieved on: 
木曜日, 5月 9, 2024
AXIN1, Research, Partnership, Clostridioides difficile infection, Development, IND, DeepMind, NVIDIA, Biomarker, Drug discovery, Tempus, Pharmacokinetics, Map, ADME, Machine learning, Software, Appetite, Roche, APC, Infection, Neurofibromatosis type II, CCM, Transcriptome, Safety, Johnson & Johnson, Neuroscience, RNA, Artificial intelligence, FAP, Data science, Therapy, Translation, Chemistry, RBM39, Biology, Clinical trial, LILAC, NF2, University of Oxford, Recurrence, Computational biology, Hemangioma, Administration, Patient, Strategy, Trial of the century, Pharmaceutical industry

L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.

Key Points: 
  • L(earnings) Call: Recursion will host a L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time.
  • Revenue: Total revenue was $13.8 million for the first quarter of 2024, compared to $12.1 million for the first quarter of 2023.
  • Research and Development Expenses: Research and development expenses were $67.6 million for the first quarter of 2024, compared to $46.7 million for the first quarter of 2023.
  • Net Loss: Net loss was $91.4 million for the first quarter of 2024, compared to a net loss of $65.3 million for the first quarter of 2023.

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
火曜日, 2月 27, 2024
FAP, Senior, Research, FPI, Chemistry, Neuroscience, AXIN1, Part, Death, LLM, Software as a service, Hemangioma, Genetics, Cancer, Software, Letter, Business operations, Data, Matchmaker, APC, Machine learning, Real space, Biology, Development, Partnership, Therapy, Enamine, CCM, Myrexis, Library, Drug discovery, Safety, Biomarker, Clinical trial, IND, Clostridioides difficile infection, Roche, NF2, Biotechnology, Neurofibromatosis type II, Trial of the century, LILAC, Disease, Myriad Genetics, Administration, Pharmaceutical industry

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.

Key Points: 
  • SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.
  • Research and Development Expenses: Research and development expenses were $69.5 million for the fourth quarter of 2023, compared to $44.0 million for the fourth quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $30.5 million for the fourth quarter of 2023 compared to $19.8 million for the fourth quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the fourth quarter of 2023, compared to a net loss of $57.5 million for the fourth quarter of 2022.

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

Retrieved on: 
木曜日, 11月 9, 2023
Research, Bayer, IND, Clostridioides difficile infection, Ovarian cancer, Hemangioma, FAP, Therapy, H100, Foundation models, Genetics, PB, SALT, Exercise, Software, Development, NF2, Pharmacokinetics, APC, NVIDIA, Clinical trial, Biology, Drug discovery, CCM, Partnership, Machine learning, Recursion, Meningioma, Personalized medicine, Benchmarking, LILAC, AXIN1, Genentech, Safety, Chemistry, Patient, Biotechnology, Map, Administration, Video game, Pharmaceutical industry, Fine chemical, Tempus

Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.

Key Points: 
  • Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $29.2 million for the third quarter of 2023, compared to $19.5 million for the third quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the third quarter of 2023, compared to a net loss of $60.4 million for the third quarter of 2022.
  • Net Cash: Net cash used in operating activities was $72.9 million for the third quarter of 2023, compared to net cash used in operating activities of $54.5 million for the third quarter of 2022.

Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results

Retrieved on: 
火曜日, 8月 8, 2023
Cloud, Clostridioides difficile infection, SALT, Chemistry, Development, CCM, Patient, ESG, SVP, DGX, Software, Partnership, Therapy, AXIN1, Drug discovery, Pharmacokinetics, Research, Genentech, International Conference on Information Systems Security and Privacy, Phenomics, Biology, Entrepreneurship, Real space, FDA, IND, Conference, Safety, Biotechnology, Toronto Office of Emergency Management, Roche, ML, Enamine, Administration, Generative, Ovarian cancer, NF2, International Conference on Machine Learning, Deep learning, Clinical trial, FAP, Proteomics, Trial of the century, Machine learning, Artificial intelligence, Wilson Sonsini Goodrich & Rosati, APC, Pharmaceutical industry, Cryptocurrency, Video game, Bayer, Cyclica, NVIDIA, Recursion

Revenue: Total revenue was $11.0 million for the second quarter of 2023, compared to $7.7 million for the second quarter of 2022.

Key Points: 
  • Revenue: Total revenue was $11.0 million for the second quarter of 2023, compared to $7.7 million for the second quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $55.1 million for the second quarter of 2023, compared to $38.4 million for the second quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $28.3 million for the second quarter of 2023, compared to $21.2 million for the second quarter of 2022.
  • Net Loss: Net loss was $76.7 million for the second quarter of 2023, compared to a net loss of $65.6 million for the second quarter of 2022.

SIAF: Disrupted epithelial barriers as a predictor of severe COVID-19 development

Retrieved on: 
月曜日, 7月 10, 2023
Permeability (electromagnetism), DNA, University of Zurich, Asthma, Obesity, Dysbiosis, University, TRANCE, Diabetes, AXIN1, Infection, COVID-19, CXCL10, End organ damage, Atopic dermatitis, Research, European Academy of Allergy and Clinical Immunology, Biomarker, Microbiota, Swiss Institute Contemporary Art New York, Journal, HIV disease progression rates, DSM-IV codes, Patient, Swiss Institute of Allergy and Asthma Research, AREG, Reading, Conditional sentence, CXCL11, Death, Allergen, Maharashtra University of Health Sciences, Autoimmunity, Rheumatoid arthritis, Inflammation, CLEC4C, Vaccine, Allergy

DAVOS, Switzerland, July 10, 2023 /PRNewswire/ -- According to the epithelial barrier theory, disruption of epithelial barriers by environmental and toxic agents triggers microbial dysbiosis, bacterial translocation to subepithelial areas and local or systemic immune/inflammatory response to environmental agents, allergens and microbes. Such events have been implicated in the development of chronic conditions like allergic, autoimmune, and metabolic diseases, such as diabetes, obesity, rheumatoid arthritis, allergies, asthma, atopic dermatitis. In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.

Key Points: 
  • In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.
  • The compromised epithelial barriers in the mucosas, particularly in gut mucosa facilitates the translocation of microbiota and their secreted metabolites, thus initiating or exacerbating inflammatory cascades in many inflammatory diseases.
  • The research group of epithelial biology in the Swiss Institute of Allergy and Asthma Research, associated with the University of Zurich, has been working on epithelial barriers for more than 20 years.
  • The authors analyzed the amount of bacterial DNA leakage to circulation and showed the link between disrupted epithelial barriers and an excessive inflammatory response.

SIAF: Disrupted epithelial barriers as a predictor of severe COVID-19 development

Retrieved on: 
月曜日, 7月 10, 2023
Permeability (electromagnetism), DNA, University of Zurich, Asthma, Obesity, Dysbiosis, University, TRANCE, Diabetes, AXIN1, Infection, COVID-19, CXCL10, End organ damage, Atopic dermatitis, Research, European Academy of Allergy and Clinical Immunology, Biomarker, Microbiota, Swiss Institute Contemporary Art New York, Journal, HIV disease progression rates, DSM-IV codes, Patient, Swiss Institute of Allergy and Asthma Research, AREG, Reading, Conditional sentence, CXCL11, Death, Allergen, Maharashtra University of Health Sciences, Autoimmunity, Rheumatoid arthritis, Inflammation, CLEC4C, Vaccine, Allergy

DAVOS, Switzerland  , July 9, 2023 /PRNewswire/ -- According to the epithelial barrier theory, disruption of epithelial barriers by environmental and toxic agents triggers microbial dysbiosis, bacterial translocation to subepithelial areas and local or systemic immune/inflammatory response to environmental agents, allergens and microbes. Such events have been implicated in the development of chronic conditions like allergic, autoimmune, and metabolic diseases, such as diabetes, obesity, rheumatoid arthritis, allergies, asthma, atopic dermatitis. In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.

Key Points: 
  • In severe cases of COVID-19, characteristic features include hyperinflammation, hyperactivated immune responses (referred to as the cytokine storm), cellular infiltration, and organ damage.
  • The compromised epithelial barriers in the mucosas, particularly in gut mucosa facilitates the translocation of microbiota and their secreted metabolites, thus initiating or exacerbating inflammatory cascades in many inflammatory diseases.
  • The research group of epithelial biology in the Swiss Institute of Allergy and Asthma Research, associated with the University of Zurich, has been working on epithelial barriers for more than 20 years.
  • The authors analyzed the amount of bacterial DNA leakage to circulation and showed the link between disrupted epithelial barriers and an excessive inflammatory response.

Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results

Retrieved on: 
月曜日, 5月 8, 2023
Acceleration, PK, Hemangioma, Partnership, NF2, Therapy, Proxy statement, AXIN1, Roche, Clinical trial, Pharmacokinetics, Intelligence, Research, FAP, History, Genentech, SALT, Chemistry, Development, Bayer, CCM, Patient, Administration, Machine learning, Map, DMPK, Drug discovery, Biology, Entrepreneurship, ESG, APC, Trial of the century, Growth, Ovarian cancer, IND, RBM39, Safety, Software, Pharmaceutical industry, Video game, Rare-earth element, Cyclica, Recursion

Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.

Key Points: 
  • Recursion expects both acquisitions to be completed in the second quarter of 2023, subject to applicable closing conditions.
  • Revenue: Total revenue was $12.1 million for the first quarter of 2023, compared to $5.3 million for the first quarter of 2022.
  • Research and Development Expenses: Research and development expenses were $46.7 million for the first quarter of 2023, compared to $32.4 million for the first quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $22.9 million for the first quarter of 2023, compared to $21.1 million for the first quarter of 2022.

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results

Retrieved on: 
月曜日, 2月 27, 2023
Clinical trial, AXIN1, Development, Safety, Genentech, RBM39, ESG, Ovarian cancer, Research, Chemistry, Firefox 3.0, Trial of the century, Partnership, Drug discovery, Chemical engineering, Algorithm, Hepatocellular carcinoma, Patient, Biology, Investment, Neuroscience, AI, CCM, FAP, APC, Culture, Therapy, Growth, Recursion, SALT, Sustainalytics, NF2, DMPK, Bayer, Roche, Administration, PK, Data, Pharmacokinetics, Data set, ML, Mobile phone, Pharmaceutical industry, Fine chemical, Cryptocurrency

Revenue: Total revenue, consisting primarily of revenue from collaborative agreements, was $13.7 million for the fourth quarter of 2022, compared to $2.5 million for the fourth quarter of 2021.

Key Points: 
  • Revenue: Total revenue, consisting primarily of revenue from collaborative agreements, was $13.7 million for the fourth quarter of 2022, compared to $2.5 million for the fourth quarter of 2021.
  • Research and Development Expenses: Research and development expenses were $44.0 million for the fourth quarter of 2022, compared to $48.3 million for the fourth quarter of 2021.
  • General and Administrative Expenses: General and administrative expenses were $19.8 million for the fourth quarter of 2022 compared to $19.2 million for the fourth quarter of 2021.
  • Net Loss: Net loss was $57.5 million for the fourth quarter of 2022, compared to a net loss of $64.9 million for the fourth quarter of 2021.